227 related articles for article (PubMed ID: 18622414)
1. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP; Khoury HJ; Langston AA
Bone Marrow Transplant; 2008 Oct; 42(8):529-34. PubMed ID: 18622414
[TBL] [Abstract][Full Text] [Related]
2. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
3. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
4. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
Evens AM; Winter JN; Hou N; Nelson BP; Rademaker A; Patton D; Singhal S; Frankfurt O; Tallman MS; Rosen ST; Mehta J; Gordon LI
Br J Haematol; 2008 Feb; 140(4):385-93. PubMed ID: 18162124
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Mantle Cell Lymphoma International Prognostic Index: A single-center retrospective analysis.
Smith SD; Hsi E; Bolwell B; Pohlman B; Dean R; Effinger M; Maggiotto A; Sweetenham J
Am J Hematol; 2010 Jun; 85(6):454-6. PubMed ID: 20513126
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma.
Laudi N; Arora M; Burns L; McGlave P; Miller J; Bohac G; Rogers T; Barker J; Coad J; Weisdorf D
Am J Hematol; 2006 Jul; 81(7):519-24. PubMed ID: 16755570
[TBL] [Abstract][Full Text] [Related]
8. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.
Thieblemont C; Antal D; Lacotte-Thierry L; Delwail V; Espinouse D; Michallet AS; Traulle C; Bouafia-Sauvy F; Giraud C; Salles G; Guilhot F; Coiffier B
Cancer; 2005 Oct; 104(7):1434-41. PubMed ID: 16104036
[TBL] [Abstract][Full Text] [Related]
10. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.
Vigouroux S; Gaillard F; Moreau P; Harousseau JL; Milpied N
Haematologica; 2005 Nov; 90(11):1580-2. PubMed ID: 16266909
[TBL] [Abstract][Full Text] [Related]
11. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.
Lefrère F; Delmer A; Levy V; Delarue R; Varet B; Hermine O
Haematologica; 2004 Oct; 89(10):1275-6. PubMed ID: 15477221
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
13. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
Olivieri A; Lucesole M; Capelli D; Gini G; Montanari M; Candela M; Troiani E; Scortechini I; Poloni A; Leoni P
Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313
[TBL] [Abstract][Full Text] [Related]
14. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
15. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
Romaguera JE; Fayad LE; Feng L; Hartig K; Weaver P; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak L; Wang M
Br J Haematol; 2010 Jul; 150(2):200-8. PubMed ID: 20528872
[TBL] [Abstract][Full Text] [Related]
16. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
Lenz G; Dreyling M; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
[TBL] [Abstract][Full Text] [Related]
17. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?
Sweetenham JW
Bone Marrow Transplant; 2001 Nov; 28(9):813-20. PubMed ID: 11781640
[TBL] [Abstract][Full Text] [Related]
18. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
19. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
20. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
Dreyling M; Hiddemann W
Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
